All News
Filter News
Found 808,674 articles
-
Iovance Biotherapeutics to Present at Upcoming Conferences in September 2022
9/6/2022
Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that senior leadership plans to present at the following conferences in September.
-
NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences
9/6/2022
NANOBIOTIX announced that Laurent Levy, Co-Founder and Chief Executive Officer of Nanobiotix, has been named to the PharmaVoice 100 list of the most inspiring people in the life sciences.
-
Occlutech Announces New Members to the Executive Management Team - Appoints Chief Commercial Officer and Vice President Global Business Development & Marketing
9/6/2022
Occlutech Holding AG, one of the world's leading providers of minimally invasive structural heart disease devices has expanded its Executive Management Team by appointing two new members.
-
Vizient Medical Device Tech Watch Highlights Trends in AI, Treatment Options for Pulmonary Embolism and Strategies to Boost Clinical Workforce Retention
9/6/2022
Vizient, Inc. released its latest Medical Device Tech Watch, identifying trends in artificial intelligence, examining treatment options for pulmonary embolism and highlighting strategies to boost clinical workforce retention.
-
Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer
9/6/2022
Homology Medicines, Inc., a genetic medicines company, announced the promotion of Albert Seymour, Ph.D., to Chief Executive Officer, President and member of the Board of Directors.
-
BioInvent Completes the Planned Dose-Escalation in Phase 1/2a trial of BI-1808 in Advanced Malignancies
9/6/2022
BioInvent International AB announces the completion of the planned dose escalation part of its Phase 1/2a trial of the anti-TNFR2 drug candidate BI-1808.
-
Biodesix to Participate in Two Upcoming Investor Conferences in September 2022
9/6/2022
Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences.
-
Tricida to Present at the H.C. Wainwright 24th Annual Global Investment Conference
9/6/2022
Tricida, Inc. announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference. Tricida will provide a company overview, business update and progress on the company’s key initiatives.
-
Kronos Bio Announces Participation in H.C. Wainwright 24th Annual Global Investment Conference
9/6/2022
Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer and other serious diseases, announced participation in the H.C. Wainwright 24th Annual Global Investment Conference.
-
ResMed Announces Participation in the 20th Annual Morgan Stanley Global Healthcare Conference
9/6/2022
ResMed announced Rob Douglas, president and chief operating officer, will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference on Monday, September 12, 2022, beginning at approximately 8:45 a.m. at the Sheraton New York in New York City.
-
Fresenius Kabi Receives U.S. FDA Approval for Biosimilar Stimufend® (pegfilgrastim - fpgk)
9/6/2022
Fresenius Kabi announced that the United States Food and Drug Administration has approved its biosimilar, Stimufend®, for use in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
-
IRLAB's partner Ipsen Initiates Clinical Studies in Line with Mesdopetam's Development Plan
9/6/2022
IRLAB Therapeutics AB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson's disease, announced that its partner Ipsen has initiated clinical studies with drug candidate mesdopetam in accordance with its development plan.
-
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September 2022
9/6/2022
Exelixis, Inc. announced that members of the company’s management team will participate in fireside chats at the following investor conferences in September.
-
S2 Genomics Announces Distribution Agreement with Techtum Lab AB to Serve Scandinavia
9/6/2022
S2 Genomics, Inc. announced that it has entered into a distribution agreement with Techtum Lab AB for the promotion, sales, and support of S2 Genomics’ Singulator™ 100 System and associated products for single-cell genomics and cell biology applications in Norway, Finland, Denmark and Sweden.
-
Alira Health Expands North American Capabilities with the Acquisition of Artisan Healthcare Consulting
9/6/2022
Alira Health, a patient-centric, global health care advisory, clinical research and technology company, announced the acquisition of Artisan Healthcare Consulting, a US-based consulting firm that provides strategic insights to healthcare companies.
-
Baptist Health’s Miami Cardiac & Vascular Institute successfully treats its first cardiac patients with new 3D Philips Intracardiac Echocardiography Catheter
9/6/2022
Royal Philips, a global leader in health technology, announced that Baptist Health’s Miami Cardiac & Vascular Institute has successfully started treating patients with Verisight Pro, Philips’ real-time 3D Intracardiac Echocardiography catheter, during minimally-invasive image-guided procedures for structural heart disease.
-
Cytokinetics to Participate in Upcoming September 2022 Investor Conferences
9/6/2022
Cytokinetics, Incorporated announced that the company is scheduled to participate in the following investor conferences.
-
Trinity Life Sciences Announces the Appointment of Maia Germain as Chief People Officer
9/6/2022
Trinity Life Sciences, a global leader in life sciences solutions, announced the appointment of Maia Germain as Chief People Officer and a member of the executive operating committee, reporting directly to Rebecca McNamara, Trinity’s CFO and Head of Corporate Operations.
-
Dong-A ST and Beactica Therapeutics mutually agree to conclude oncology collaboration
9/6/2022
Dong-A ST Co., Ltd., a Korean pharmaceutical company, and Beactica Therapeutics AB, a Swedish precision oncology company, announced that they have mutually agreed to terminate their collaboration and licensing agreement.
-
Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy
9/6/2022
IVERIC bio, Inc. announced positive topline results from GATHER2, the Company’s second Phase 3 clinical trial of Zimura®, a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy.